Search results
Results from the WOW.Com Content Network
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors. [1] [2] [3] [4]
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a mid ...
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
Medical research for cancer begins much like research for any disease. In organized studies of new treatments for cancer, the pre-clinical development of drugs, devices, and techniques begins in laboratories, either with isolated cells or in small animals, most commonly rats or mice. In other cases, the proposed treatment for cancer is already ...
the first-line treatment of advanced renal cell carcinoma (RCC) in adults in combination with axitinib. [13] In June 2020, the US FDA approved a new indication for pembrolizumab as the first-line treatment for people with unresectable or metastatic microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) colorectal cancer. [17]
Vinorelbine is one of the drugs that are used for cancer treatment. Using vinorelbine as a regimen was shown to be feasible for very elderly patients who tend to have multiple comorbidities which is a condition that a patient has more than two diseases at a time, and require multiple medications [ 20 ] but, the effect of metronomic therapy is ...
The drug (originally known as MT103) was developed by a German-American company Micromet, Inc. in cooperation with Lonza; In 2012, Micromet was purchased by Amgen, which furthered the drug's clinical trials. In July 2014, the FDA granted breakthrough therapy status to blinatumomab for the treatment of acute lymphoblastic leukemia (ALL). [12]